Evgen Pharma

Evgen Pharma is a clinical stage drug development company focused on the treatment of cancer and neurological conditions. Evgen’s pipeline is based on our proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications. Our objective is to use our Sulforadex® technology to turn this scientific promise into commercially successful products.
Company Growth (employees)
Liverpool, GB
Size (employees)
2 (est)
Evgen Pharma was founded in 2007 and is headquartered in Liverpool, GB

Evgen Pharma Office Locations

Evgen Pharma has offices in Liverpool and London
Liverpool, GB (HQ)
Liverpool Science Park Innovation Centre 2 146 Brownlow Hill
London, GB
107 Cheapside

Evgen Pharma Data and Metrics

Evgen Pharma Financial Metrics


Net income (FY, 2016)

(3.1 m)

Market capitalization (25-Jul-2017)

12.5 m

Closing share price (25-Jul-2017)


Cash (31-Mar-2016)

5.1 m
Evgen Pharma's current market capitalization is £12.5 m.
GBPFY, 2015FY, 2016

Pre tax profit

(2.3 m)(3.2 m)

Net Income

(2.3 m)(3.1 m)
GBPFY, 2015FY, 2016


163 k5.1 m

Accounts Receivable

6 k3 k

Current Assets

310 k7.3 m


1 k6 k


45 k74 k

Total Assets

356 k7.4 m

Accounts Payable

130 k86 k

Current Liabilities

480 k313 k

Total Liabilities

1.5 m313 k

Retained Earnings

(2.3 m)(3.1 m)

Total Equity

(1.2 m)7.1 m

Financial Leverage

-0.3 x1 x
GBPFY, 2015FY, 2016

Cash From Operating Activities

(900 k)(1.6 m)

Cash From Financing Activities

750 k8.6 m

Income Taxes Paid

30 k85 k
Y, 2016

Financial Leverage

1 x

Evgen Pharma Market Value History

Traffic Overview of Evgen Pharma

Evgen Pharma Online and Social Media Presence

Evgen Pharma Company Life and Culture

You may also be interested in